TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10809860

Group type: EXPERIMENTAL
Intervention: Topically applied NG-monomethyl-L-arginine (L-NMMA) in aqueous cream BP
Number of subjects: 17

Group type: COMPARATOR
Intervention: Aqueous cream BP alone (control)
Number of subjects: 17
Study: 8752293

Group type: EXPERIMENTAL
Intervention: Quadrivalent rhesus rotavirus-based human rotavirus vaccine
Number of subjects: 0
Study: 1802904

Group type: EXPERIMENTAL
Intervention: Eutectic mixture of lidocaine and prilocaine (EMLA) 5 gm applied for 1 hour before diathermy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo applied for 1 hour before diathermy
Number of subjects: 21
Study: 6882194

Group type: EXPERIMENTAL
Intervention: Doubling of the pre-beta lipoprotein band in diabetics (8 cases observed)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (10 controls chosen at random)
Number of subjects: 100
Study: 31513481

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 87
Study: 29565762

Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU (treatment)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ergocalciferol 400 IU (control)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Crossover from control to treatment group (for months 6-10)
Number of subjects: 49
Study: 26462724

Group type: EXPERIMENTAL
Intervention: G-CSF (6 mg administered subcutaneously every 2 weeks for 12 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 14
Study: 25417120

Group type: EXPERIMENTAL
Intervention: Light-masks used during sleep at night for 24 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control masks (with no light) used during sleep at night for 24 months
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Light-masks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control masks
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Light-masks and supplemental oxygen
Number of subjects: 300
Study: 22587573

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5% drops
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 30
Study: 19799615

Group type: EXPERIMENTAL
Intervention: Cold-turkey smoking cessation for 24 hours
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) for 29 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy non-smokers (control group)
Number of subjects: 23
Study: 17566099

Group type: EXPERIMENTAL
Intervention: ghrelin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: human CRH
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: l-arginine with ghrelin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: l-arginine with CRH
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ghrelin and CRH with l-arginine
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline
Number of subjects: 10
Study: 15810767

Group type: EXPERIMENTAL
Intervention: Experimental group practiced the skill with the hand opposite the one used during the pretest until they reached a designated criterion for their age.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group performed a balancing activity.
Number of subjects: 160
Study: 12556542

Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 281

Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 281
Study: 11074392

Group type: EXPERIMENTAL
Intervention: Timing of surgery for subarachnoid haemorrhage (SAH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study: 8898143

Group type: EXPERIMENTAL
Intervention: Local corticosteroid injections
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cyriax-type physiotherapy
Number of subjects: 106
Study: 1651304

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 187

Group type: COMPARATOR
Intervention: Chest irradiation alone
Number of subjects: 187

Group type: COMPARATOR
Intervention: Adjuvant chest irradiation alone
Number of subjects: 187
Study: 6152880

Group type: COMPARATOR
Intervention: Beta-receptor blockade continued until surgery (n = 48)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Beta-receptor blockade gradually withdrawn (n = 51)
Number of subjects: 91
Study: 31478300

Group type: EXPERIMENTAL
Intervention: Psychotropic medications
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Challenging behaviour
Number of subjects: 138
Study: 30835307

Group type: COMPARATOR
Intervention: Placebo without therapy (n=257)
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Placebo with therapy (n=256)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Supplements without therapy (n=256)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Supplements with therapy (n=256)
Number of subjects: 1025
Study: 29039320

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg fast dispersible tablets (test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Marketed (reference) product
Number of subjects: 12
Study: 25652579

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy for insomnia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Internet-based control program
Number of subjects: 80
Study: 24352348

Group type: EXPERIMENTAL
Intervention: Nevirapine or abacavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine plus lamivudine
Number of subjects: 0
Study: 21561896

Group type: EXPERIMENTAL
Intervention: GLP‐1 infusion at 1.2 pmol/kg/min starting 30 min before dobutamine stress echocardiography (DSE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GLP‐1 infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no GLP‐1 infusion)
Number of subjects: 14
Study: 19571733

Group type: EXPERIMENTAL
Intervention: MRI substudy enrollers
Number of subjects: 327

Group type: COMPARATOR
Intervention: Nonenrollers
Number of subjects: 327
Study: 17475965

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT with delayed images after furosemide and oral hydration
Number of subjects: 17
Study: 10721881

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8836320

Group type: EXPERIMENTAL
Intervention: Binaural auditory stimuli with ISIs of 0.5, 1.0, and 10.0 s
Number of subjects: 50
Study: 1579628

Group type: EXPERIMENTAL
Intervention: Bromazepam (6 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bromazepam (12 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bromazepam (6 mg and 12 mg)
Number of subjects: 30
Study: 4040550

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (120 mg/m2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low-dose cisplatin (60 mg/m2)
Number of subjects: 64
Study: 31319633

Group type: EXPERIMENTAL
Intervention: MCT in liquid form (MCT-L)
Number of subjects: 29

Group type: COMPARATOR
Intervention: LCT in liquid form (Con-L)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MCT in solid form (MCT-S)
Number of subjects: 29

Group type: COMPARATOR
Intervention: LCT in solid form (Con-S)
Number of subjects: 29
Study: 30204905

Group type: EXPERIMENTAL
Intervention: 3 iso-energetic breakfasts
Number of subjects: 15

Group type: COMPARATOR
Intervention: Energy-free control meal
Number of subjects: 15
Study: 27476722

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study: 24715249

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA + standard of care
Number of subjects: 273

Group type: COMPARATOR
Intervention: placebo + standard of care
Number of subjects: 273
Study: 23431840

Group type: EXPERIMENTAL
Intervention: Video presentation group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Illustrated book group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both video presentation and illustrated book group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 20920261

Group type: EXPERIMENTAL
Intervention: Xylitol lozenges
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 691
Study: 18823202

Group type: EXPERIMENTAL
Intervention: Active gaze sampling with natural looking patterns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unnatural looking patterns
Number of subjects: 0
Study: 15932659

Group type: EXPERIMENTAL
Intervention: Spironolactone 40 mg/d
Number of subjects: 88

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 88
Study: 12460700

Group type: EXPERIMENTAL
Intervention: CC genotype in white participants with treated hypertension
Number of subjects: 2171

Group type: COMPARATOR
Intervention: AA genotype in white participants with treated hypertension
Number of subjects: 2171

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 2171

Group type: EXPERIMENTAL
Intervention: CC genotype in white participants
Number of subjects: 2171
Study: 10342710

Group type: EXPERIMENTAL
Intervention: DHEA 200 mg/d
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7500633

Group type: EXPERIMENTAL
Intervention: Mouthpiece/noseclip (BV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mouth/face mask (MM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Facemask (FM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mouthpiece/noseclip (BV), Mouth/face mask (MM), Facemask (FM)
Number of subjects: 10
Study: 1773202

Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31758564

Group type: EXPERIMENTAL
Intervention: Alcohol intervention plus booster email
Number of subjects: 537

Group type: COMPARATOR
Intervention: Alcohol intervention only
Number of subjects: 537

Group type: COMPARATOR
Intervention: General health education
Number of subjects: 537
Study: 31205435

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 28
Study: 29926711

Group type: COMPARATOR
Intervention: 20 μg HBV vaccine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 40 μg HBV vaccine
Number of subjects: 39
Study: 26542491

Group type: EXPERIMENTAL
Intervention: liraglutide (1.8 mg before intervention, followed by 0.6 mg for 2 days, 1.2 mg for 2 days, and 1.8 mg for 3 days)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 92

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study: 23524424

Group type: EXPERIMENTAL
Intervention: Flowable glass-ionomer cement (GIC) as a liner in proximal-ART restorations; two-layer technique with Ketac Molar Easymix; operators had no experience or two years of experience, both trained for one week.
Number of subjects: 45
Study: 21939561

Group type: EXPERIMENTAL
Intervention: ε4 carriers
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Non-carriers of ε4 allele
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1402
Study: 21118564

Group type: EXPERIMENTAL
Intervention: High intensity exercise programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 17690713

Group type: EXPERIMENTAL
Intervention: Antigen-specific therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental models and clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advances in antigen-specific therapies
Number of subjects: 0
Study: 15611327

Group type: EXPERIMENTAL
Intervention: Early Intervention Foster Care Program (EIFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular foster care comparison condition
Number of subjects: 0
Study: 12169965

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 60
Study: 10628519

Group type: EXPERIMENTAL
Intervention: Assertiveness building prevention program
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Modeling and social inference prevention program
Number of subjects: 206

Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 206
Study: 8519716

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (group 2)
Number of subjects: 38
Study: 2191712

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (400 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Acyclovir ophthalmic ointment (3%)
Number of subjects: 43
Study: 6970007

Group type: EXPERIMENTAL
Intervention: ICI 35868 (Diprivan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study: 31775064

Group type: EXPERIMENTAL
Intervention: Daily assessment schedule
Number of subjects: 307

Group type: COMPARATOR
Intervention: Weekly assessment schedule
Number of subjects: 307
Study: 31420412

Group type: EXPERIMENTAL
Intervention: Primary cytoreductive surgery followed by 6 cycles of platinum-based chemotherapy
Number of subjects: 772

Group type: COMPARATOR
Intervention: Interval cytoreductive surgery following 3 cycles of neoadjuvant chemotherapy and then 3 cycles of platinum-based chemotherapy
Number of subjects: 772
Study: 25442641

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan toothpaste
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 438
Study: 23334782

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg po one hour before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21335931

Group type: EXPERIMENTAL
Intervention: Cervical spine thrust manipulation (TJM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thoracic spine thrust manipulation (TJM)
Number of subjects: 24
Study: 18930378

Group type: EXPERIMENTAL
Intervention: Social cognition skills training intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Time-matched control condition (illness self-management and relapse prevention skills training)
Number of subjects: 31
Study: 16508700

Group type: EXPERIMENTAL
Intervention: 1,200 mg calcium plus 800 IU cholecalciferol (n=33)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1,200 mg calcium (n=31)
Number of subjects: 64
Study: 15284525

Group type: EXPERIMENTAL
Intervention: Cerebral palsy patients undergoing PSF
Number of subjects: 2

Group type: COMPARATOR
Intervention: Idiopathic scoliosis patients undergoing PSF
Number of subjects: 2
Study: 11775134

Group type: EXPERIMENTAL
Intervention: 600 mg eprosartan
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 1200 mg eprosartan
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 8985257

Group type: EXPERIMENTAL
Intervention: Antimitochondrial autoantibodies (AMA) measured by indirect immunofluorescence (IF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimitochondrial autoantibodies (AMA) measured by quantitative enzyme immunoassays (EIAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levels of AMA to 2‐OADC proteins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurements of AMA by IF or by quantitative EIA methods with recombinant 2‐OADC proteins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levels of autoantibodies to 2‐OADC proteins
Number of subjects: 0
Study: 8276044

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at 0.02 microgram.kg‐1.min‐1 infusion during bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 20
Study: 2964340

Group type: EXPERIMENTAL
Intervention: Penicillin (P)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Spectinomycin (S)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Overall resistance to penicillin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Overall resistance to spectinomycin
Number of subjects: 72
Study: 29438468

Group type: EXPERIMENTAL
Intervention: Variety 'Jefferson'
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Variety 'Jupiter'
Number of subjects: 2

Group type: COMPARATOR
Intervention: Choice tests
Number of subjects: 2

Group type: COMPARATOR
Intervention: No-choice tests
Number of subjects: 2

Group type: COMPARATOR
Intervention: Choice and no-choice tests
Number of subjects: 2
Study: 27029592

Group type: EXPERIMENTAL
Intervention: HeartSmartKids™
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-HeartSmartKids™
Number of subjects: 33
Study: 24711047

Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: GPI‐1485
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 22747667

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20573187

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 920

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 920

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 920
Study: 18771678

Group type: EXPERIMENTAL
Intervention: Structural representations learned for 3D objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: View-specific representations
Number of subjects: 0
Study: 15692354

Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Number of subjects: 34

Group type: COMPARATOR
Intervention: Static splinting
Number of subjects: 34
Study: 11876707

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/day) and lansoprazole (30 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/day), lansoprazole (30 mg/day), and clarithromycin (500 mg b.d.)
Number of subjects: 120
Study: 10196074

Group type: EXPERIMENTAL
Intervention: Exposure to misleading questions after viewing an event
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single exposure to the event
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple exposures to the event
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to misinformation once or three times
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control for differences in trace strength
Number of subjects: 0
Study: 8579350

Group type: EXPERIMENTAL
Intervention: Differential reinforcement of incompatible behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time‐out from positive reinforcement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 0
Study: 2082306

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 125
Study: 314724

Group type: EXPERIMENTAL
Intervention: Surgical treatment (bypass surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study: 29306453

Group type: EXPERIMENTAL
Intervention: Caffeine containing weight loss supplement
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 27389521

Group type: EXPERIMENTAL
Intervention: Brief integrated intervention
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Nine further sessions of integrated treatment
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Nine further sessions of alcohol-focused treatment
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Nine further sessions of depression-focused treatment
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Integrated interventions (incorporating motivational interviewing and cognitive behaviour therapy)
Number of subjects: 290
Study: 24284025

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1245
Study: 22795645

Group type: EXPERIMENTAL
Intervention: Oxytocin administration to father
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo administration to father
Number of subjects: 35
Study: 20082715

Group type: EXPERIMENTAL
Intervention: Melatonin alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Omeprazole alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of melatonin and omeprazole
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study: 18363810

Group type: EXPERIMENTAL
Intervention: Down's syndrome individuals (DS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Controls (CONT)
Number of subjects: 14
Study: 16137357

Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CV)
Number of subjects: 61
Study: 12207630

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tap water (200 ml)
Number of subjects: 10
Study: 10792845

Group type: EXPERIMENTAL
Intervention: G-CSF (0.3 mg/ml, 3 times a week for 12 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8777829

Group type: EXPERIMENTAL
Intervention: CO2-enriched (5%) gas mixture with low-dose scopolamine (scopoderm TTS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Voluntary hyperventilation with low-dose scopolamine (scopoderm TTS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CO2-enriched (5%) gas mixture without scopolamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Voluntary hyperventilation without scopolamine
Number of subjects: 8
Study: 1501087

Group type: EXPERIMENTAL
Intervention: Planned extracapsular extraction with PMMA IOL implantation (11 mm incision)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with PMMA IOL implantation (7 mm incision)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with foldable silicone single‐piece IOL implantation (4 mm incision)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Age-matched normal controls
Number of subjects: 120